W

Walvax Biotechnology Co Ltd
SZSE:300142

Watchlist Manager
Walvax Biotechnology Co Ltd
SZSE:300142
Watchlist
Price: 14.8 CNY 0.48% Market Closed
Market Cap: 23.7B CNY
Have any thoughts about
Walvax Biotechnology Co Ltd?
Write Note

Walvax Biotechnology Co Ltd
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Walvax Biotechnology Co Ltd
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
W
Walvax Biotechnology Co Ltd
SZSE:300142
Cash & Cash Equivalents
ÂĄ3.3B
CAGR 3-Years
14%
CAGR 5-Years
8%
CAGR 10-Years
18%
Beigene Ltd
HKEX:6160
Cash & Cash Equivalents
ÂĄ15B
CAGR 3-Years
33%
CAGR 5-Years
32%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Cash & Cash Equivalents
ÂĄ3.8B
CAGR 3-Years
75%
CAGR 5-Years
55%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Cash & Cash Equivalents
ÂĄ1.9B
CAGR 3-Years
-1%
CAGR 5-Years
13%
CAGR 10-Years
7%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Cash & Cash Equivalents
ÂĄ5.6B
CAGR 3-Years
9%
CAGR 5-Years
38%
CAGR 10-Years
20%
Imeik Technology Development Co Ltd
SZSE:300896
Cash & Cash Equivalents
ÂĄ2.4B
CAGR 3-Years
-11%
CAGR 5-Years
56%
CAGR 10-Years
N/A
No Stocks Found

Walvax Biotechnology Co Ltd
Glance View

Market Cap
23.8B CNY
Industry
Biotechnology

Walvax Biotechnology Co., Ltd. engages in the research and development, production, and sale of biopharmaceutical products. The company is headquartered in Kunming, Yunnan and currently employs 1,866 full-time employees. The company went IPO on 2010-11-12. The Company’s main products include haemophilus influenza type b conjugate vaccines, freeze-dried group A,C meningococcal polysaccharide conjugate vaccines, group ACYW135 meningococcal polysaccharide vaccines and group A and C meningococcal polysaccharide vaccines, among others. The firm distributes its products mainly in domestic market.

Intrinsic Value
15.56 CNY
Undervaluation 5%
Intrinsic Value
Price
W

See Also

What is Walvax Biotechnology Co Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
3.3B CNY

Based on the financial report for Jun 30, 2024, Walvax Biotechnology Co Ltd's Cash & Cash Equivalents amounts to 3.3B CNY.

What is Walvax Biotechnology Co Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
18%

Over the last year, the Cash & Cash Equivalents growth was -14%. The average annual Cash & Cash Equivalents growth rates for Walvax Biotechnology Co Ltd have been 14% over the past three years , 8% over the past five years , and 18% over the past ten years .

Back to Top